药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Enprofylline
Ibudilast
The risk or severity of bleeding can be increased when Ibudilast is combined with Mitoxantrone.
Enprofylline
Beraprost
The risk or severity of bleeding can be increased when Beraprost is combined with Mitoxantrone.
Enprofylline
Defibrotide
The risk or severity of bleeding can be increased when Defibrotide is combined with Mitoxantrone.
Enprofylline
Resveratrol
The risk or severity of bleeding can be increased when Resveratrol is combined with Mitoxantrone.
Enprofylline
Epoprostenol
The risk or severity of bleeding can be increased when Epoprostenol is combined with Mitoxantrone.
Enprofylline
Ridogrel
The risk or severity of bleeding can be increased when Ridogrel is combined with Mitoxantrone.
Enprofylline
Moderna COVID-19 Vaccine
The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Mitoxantrone.
Enprofylline
Ebola Zaire vaccine (live, attenuated)
The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Mitoxantrone.
Enprofylline
Modified vaccinia ankara
The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Mitoxantrone.
Enprofylline
Varicella Zoster Vaccine (Recombinant)
The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Mitoxantrone.
Enprofylline
Yersinia pestis 195/p antigen (formaldehyde inactivated)
The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Mitoxantrone.
Enprofylline
Pertussis vaccine
The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Mitoxantrone.
Enprofylline
Smallpox (Vaccinia) Vaccine, Live
The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Mitoxantrone.
Enprofylline
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Mitoxantrone.
Enprofylline
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Mitoxantrone.
Enprofylline
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Mitoxantrone.
Enprofylline
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Mitoxantrone.
Enprofylline
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Mitoxantrone.
Enprofylline
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Mitoxantrone.
Enprofylline
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Mitoxantrone.